Live
BioPharma DiveKardigan extends biotech’s streak of big IPOs with $400M haulEndpoints NewsKardigan raises $400M in IPO to back three clinical-stage cardio drugsEndpoints NewsBiogen makes up to $1B deal for secretive anti-inflammatory biotechFierceBiotech‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC gameClinical OMICsHave Microbubbles Burst Through the Barriers of Genetic Medicine Delivery?AgilentAgilent (A) Has a Consumables-and-Service Analytical Platform Bigger Than a Biotech-Funding Proxy - AlphaStreetClinical OMICsOLE Identified as a Potential Alzheimer’s Therapy Targeting MicrogliaEndpoints NewsFDA gives rejected drugs another chance in post-Makary era10x Genomics Blog10x Genomics (TXG) Launches Cleveland Clinic Partnership For Bladder Cancer Diagnostics - simplywall.st10x Genomics Blog10x Genomics (TXG) Launches Cleveland Clinic Partnership For Bladder Cancer Diagnostics - simplywall.stClinical OMICsAI Discovers Two New Antibiotics for Drug-Resistant GonorrheaClinical OMICsGLP-1 Drugs Reduce Crime-Linked Behavior
Endpoints News Jan 27, 2026

CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations

CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations

Body unavailable. Use the original source.